How is methaemoglobinemia diagnosed and treated?

Diagnosis and Treatment of Methemoglobinemia

Diagnosis

Suspect methemoglobinemia when a patient presents with cyanosis unresponsive to oxygen therapy, low oxygen saturation on pulse oximetry despite normal arterial pO₂, and chocolate-brown colored blood. 1, 2

Clinical Presentation by Severity

• 10–30% MetHb: Cyanosis, headache, tachycardia, mild dyspnea with minimal acidosis 3
• 30–50% MetHb: Clinically significant tissue hypoxia with developing lactic acidosis 3
• >50% MetHb: Profound metabolic acidosis, dysrhythmias, seizures, altered mental status, and cardiovascular collapse risk 3
• >70% MetHb: Potentially lethal with severe high-anion-gap metabolic acidosis 3

Diagnostic Features

• Patients appear more cyanotic than their clinical condition suggests—they are often less unwell than expected from the severity of discoloration 1
• Pulse oximetry is unreliable and does not accurately reflect true oxygen saturation 1
• Arterial blood gas analysis reveals normal pO₂ and pCO₂, normal calculated oxygen saturation, elevated methemoglobin concentration, and possible metabolic acidosis 1
• The blood adopts a characteristic brown-bluish or chocolate-brown appearance that can be used diagnostically 4, 2

Obtain Critical History

• Exposure to oxidizing agents: local anesthetics (benzocaine, lidocaine), antimalarials (chloroquine, primaquine), antibiotics (sulfonamides, trimethoprim), dapsone, phenazopyridine, metoclopramide 5, 6, 4
• Contaminated well water or food with excessive nitrates, particularly in infants and pregnant women 6
• Family history suggesting inherited forms (CYB5R3 mutations, hemoglobin M disease) 6
• G6PD deficiency status before treatment—this is mandatory 5

---

Treatment

Administer intravenous methylene blue 1–2 mg/kg over 3–5 minutes immediately for symptomatic patients or those with methemoglobin levels >20%, but only after confirming the patient does NOT have G6PD deficiency. 5

Pre-Treatment Screening (Critical)

• Screen for G6PD deficiency before giving methylene blue—methylene blue causes severe hemolytic anemia and paradoxically worsens methemoglobinemia in G6PD-deficient patients 5, 1
• Assess for concurrent SSRI or serotonergic medication use due to serotonin syndrome risk 5
• Determine pregnancy status, as methylene blue is teratogenic 5

Methylene Blue Administration Protocol

• Initial dose: 1–2 mg/kg (0.2 mL/kg of 1% solution) IV over 3–5 minutes 3, 5
• Methemoglobin levels typically decrease within 30–60 minutes, with parallel improvement in acid-base status 3, 5
• Repeat dose: 1 mg/kg can be given if no improvement after 30–60 minutes 5
• Maximum cumulative dose: Do not exceed 7 mg/kg total to avoid toxicity and paradoxical worsening 3, 5

Treatment Thresholds

• Symptomatic patients with MetHb >20%: Treat 5
• Asymptomatic patients with MetHb >30%: Treat 5
• Symptomatic patients with MetHb 10–30% plus risk factors (infants, cardiac/respiratory disease, baseline anemia): Treat 3, 5

Supportive Care

• Decontaminate the patient immediately to prevent continued absorption 5
• Administer high-flow oxygen to maximize oxygen carriage by remaining functional hemoglobin 1
• Establish IV access with aggressive hydration 5
• Ensure adequate glucose availability—essential for endogenous reducing enzymes and for methylene blue efficacy via NADPH production 5
• Provide cardiopulmonary support with mechanical ventilation and pressors if needed 5

Critical Management Pitfall

Do NOT postpone methylene blue to first correct metabolic acidosis—the acidosis resolves only after oxygen delivery is restored by reducing methemoglobin levels. 3

---

Rescue Therapy for Refractory Cases

When Methylene Blue Fails or Is Contraindicated

• Exchange transfusion achieves 81.6% survival in patients unresponsive to methylene blue, directly removing MetHb and supplying functional hemoglobin 3, 5
• Hyperbaric oxygen therapy provides modest additional oxygen delivery despite MetHb presence 3, 5, 7

G6PD Deficiency Management

• Methylene blue is contraindicated in G6PD deficiency 5, 1
• Use ascorbic acid as primary treatment instead—can be administered orally, intramuscularly, or intravenously 5
• Exchange transfusion is the preferred alternative for life-threatening cases 5, 1

Pregnancy Considerations

• Methylene blue should only be used when hypoxia risk outweighs teratogenic risk 5
• Exchange transfusion should be considered as a safer alternative in pregnant patients 5

---

High-Risk Populations Requiring Lower Treatment Thresholds

• Infants: Lower erythrocyte CYB5R activity makes them prone to more severe acidosis and methemoglobinemia 3, 6
• Pre-existing cardiac or respiratory disease: Develop acidosis at lower MetHb thresholds and deteriorate more rapidly 3
• Baseline anemia: Reduced oxygen-carrying reserve leads to earlier tissue hypoxia and acidosis 3